--- title: 'Industry Daily Summary: What Happened on November 3, 2026' headline: Stryker invests $400 million in CMR Surgical and gains option to buy it description: AstraZeneca set a cost-cutting target, Karyopharm entered bankruptcy and the FDA set a decision date for uniQure’s Huntington’s disease therapy. url: https://thebench.bio/news/industry/2026-11-03 topic: industry date: '2026-11-03' covers: - '2026-11-03' date_published: '2026-11-03T12:03:20Z' date_modified: '2026-11-03T12:03:20Z' tags: - Industry - Funding sources: 3 publisher: TheBench.Bio --- # Industry Daily Summary: What Happened on November 3, 2026 **Stryker invests $400 million in CMR Surgical and gains option to buy it** AstraZeneca set a cost-cutting target, Karyopharm entered bankruptcy and the FDA set a decision date for uniQure’s Huntington’s disease therapy. ## Today in brief Stryker will invest about $400 million in CMR Surgical, gain exclusive US commercial rights to its Versius robots and hold an option to acquire the company. [1] AstraZeneca is targeting $1.5 billion in annual savings by 2029. The FDA set May 1, 2027, as its decision date for uniQure’s Huntington’s disease application. [2] ## Stryker backs CMR Surgical and could acquire the company Stryker will invest about $400 million in CMR Surgical and gain exclusive US commercial rights to CMR’s Versius surgical robotics portfolio. [1] Stryker also secured an option to buy all of CMR’s outstanding equity in a later transaction, subject to the agreement’s terms. [1] CMR will continue developing Versius and selling it outside the US. [1] The investment and commercial arrangement still needs regulatory approval and must meet customary closing conditions. [1] ## Also worth knowing - The UK Health Security Agency awarded Bavarian Nordic a four-year contract to supply MVA-BN, a vaccine used to prevent mpox and smallpox. [3] - Karyopharm filed for Chapter 11 bankruptcy on November 2. Ayrmid agreed to act as lead bidder in a potential acquisition, which requires court approval and remains open to competing offers. [2] - Dosing the fifth participant in a European Phase 3 study of Sanofi’s Nuvaxovid with a high-dose flu vaccine triggered a $125 million milestone payment to Novavax. [2] ## The day in numbers - **$400 million**: Approximate investment Stryker agreed to make in CMR Surgical. [1] - **$1.5 billion a year**: AstraZeneca’s savings target by the end of 2029. [2] - **May 1, 2027**: FDA decision date for uniQure’s AMT-130 application. [2] ## Also published - [EnteroBiotix appoints former GSK Chief Medical Officer to board](), Pharmafile - [Radiology has been optimising the wrong metric](), pharmaphorum - [LEAP HR: Life Sciences Europe](), pharmaphorum - [Solution Spotlight: BrandPRO Biopharma](), pharmaphorum - [ESMO’s first-in-human signals, Auchincloss’ proposal & COINS reaction — a BioCentury podcast](), BioCentury ## Sources 1. [Stryker invests US$400m in CMR Surgical and secures option to acquire business](), Pharmafile, 2026-11-03 2. [AstraZeneca targets $1.5B in savings; Ayrmid bids for Karyopharm; Sanofi pays $125M to Novavax](), European Biotechnology, 2026-11-03 3. [Bavarian Nordic secures four-year UK vaccine supply deal](), Pharmaceutical Technology, 2026-11-03 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: [3]: